Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer

Journal of Breast Cancer

Volumn 17, Issue 2, 2014, Pages 113-120

  Shin, Su Jin ^a   Gong, Gyungyub ^a   Lee, Hee Jin ^a   Kang, Jun ^b   Bae, Young Kyung ^c   Lee, Ahwon ^b   Cho, Eun Yoon ^d   Lee, Ji Shin ^e   Suh, Kwang Sun ^f   Lee, Dong Wha ^g   Jung, Woo Hee ^h  

^a University of Ulsan College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Chonnam National University Medical School   (South Korea)

^f Chungnam National University College of Medicine   (South Korea)

^g Soonchunhyang University College of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Immunohistochemistry; Insulin like growth factor 1 receptor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PROGNOSIS; CELL HETEROGENEITY; COLLOID CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT OUTCOME;

EID: 84903937903     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2014.17.2.113     Document Type: Article

References (25)

1. Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990;50:48-53.
2. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
3. Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004;64:286-291.
4. Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:485-498.
5. Pegram MD, Pietras R, Bajamonde A, Klein P, Fyfe G. Targeted therapy: wave of the future. J Clin Oncol 2005;23:1776-1781.
6. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004; 13:1569-1577.
7. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth fac-tor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-1857.
8. Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract 2012;2012:648965.
9. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-4618.
10. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jefrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
11. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-8423.
12. van'T Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
13. Law JH, Habibi G, Hu K, Masoudi H, Wang M Y, Stratford AL, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-10246.
14. Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012;132:131-142.
15. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995;26:873-879.
16. Elston C W, Ellis IO. Pathological prognostic factors in breast cancer. I. Te value of histological grade in breast cancer: experience from a large study with long-term follow-up. C. W. Elston & I. O. Ellis. Histopathol-ogy 1991; 19; 403-410. Histopathology 2002;41(3A):151-152.
17. Bae YK, Gong G, Kang J, Lee A, Cho E Y, Lee JS, et al. HER2 status by standardized immunohistochemistry and silver-enhanced in situ hybridization in Korean breast cancer. J Breast Cancer 2012;15:381-387.
18. Wolf AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
19. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005;23:7350-7360.
20. Bonneterre J, Peyrat J P, Beuscart R, Demaille A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res 1990;50:6931-6935.
21. Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamagu-chi Y, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53:3736-3740.
22. Shin A, Ren Z, Shu XO, Cai Q, Gao Y T, Zheng W. Expression patterns of insulin-like growth factor 1 (IGF-I) and its receptor in mammary tissues and their associations with breast cancer survival. Breast Cancer Res Treat 2007;105:55-61.
23. Gallardo A, Lerma E, Escuin D, Tibau A, Muñoz J, Ojeda B, et al. Increased signaling of EGFR and IGF1R, and deregulation of PTEN/ PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 2012;106:1367-1373.
24. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750-2767.
25. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008;68:1538-1545.